Latest news

Baylis Medical Expands Transseptal Portfolio with Launch of Steerable Guiding Sheath

Date:

Baylis Medical Expands Transseptal Portfolio with Launch of Steerable Guiding Sheath

TORONTO, SEPTEMBER 10, 2018 – Baylis Medical Company, a leader in the development, manufacturing and commercialization of cardiology devices, announced the official commercial launch of its SureFlex® Steerable Guiding Sheath. 

The SureFlex sheath is part of Baylis’ rapidly growing portfolio of high-performance products for transseptal access. The sheath features an advanced sheath-to-dilator design for controlled crossing of the septum, intuitive and high-precision steering, and reliable performance through superior curve retention and consistent sheath tip contact force.

Steerable sheaths facilitate access in complex anatomies and hard-to-reach areas in the left side of the heart. Dr. Brian Powell, Medical Director of Electrophysiology practicing in Charlotte, North Carolina, finds them helpful with improving contact and subsequent outcomes in procedures such as atrial fibrillation and ventricular tachycardia ablations.

“When contact force sensing technology became available, it was an eye opener how much a steerable sheath improves contact,” said Dr. Powell. “The SureFlex sheath has good maneuverability and control. With the SureFlex sheath, I have not seen the flexion fatigue during long cases that I have experienced with similar sheaths. It maintains its ability to curl throughout the entire procedure.” 

If a steerable sheath’s contact force and tip range of motion are not maintained during a procedure, it may result in clinical failure and necessitate additional revision procedures for the patient.

“Baylis is committed to continually developing sophisticated solutions that meet the needs of physicians, allowing them to deliver life-saving therapies to their patients,” said Neil Godara, Director of Research and Development at Baylis. “The launch of SureFlex further demonstrates our dedication to excellence in transseptal access following the global success of our NRG® Transseptal Needle.”

Media Contact
Elissa Hanna
Corporate Communications Manager
Baylis Medical Company
media@baylismedical.com

About Baylis Medical Company Inc.
Baylis Medical is a world leader in the development and commercialization of high-performance cardiology devices that help physicians deliver life-changing therapies to patients. Headquartered in Canada, and with offices world-wide, our clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com and connect with us on Twitter, LinkedIn and Instagram.

PRM-00358 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2018. SureFlex, NRG and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.

Journeying from Star Wars® to blankets

Date:

Journeying from Star Wars® to blankets

Amanda Martyn, Senior Quality Assurance Analyst at Baylis Medical, picked up a crochet hook for the first time when her husband gave her a book on how to crochet Star Wars characters. She quickly began crocheting Star Wars-themed toys for her son, Jay.

Two years later, although she is no longer creating an army of Stormtroopers® for her son to enjoy, she still uses yarn for a different purpose — providing comfort and a feeling of security to children who are “seriously ill, traumatized or otherwise in need.”1

 She and other devoted members of the Baylis Yarncraft Club are doing this by making blankets for Project Linus, an organization appropriately named after the beloved Peanuts character, Linus van Pelt, who is rarely seen without his blue security blanket. In addition to monetary donations and knitting supplies, Project Linus also accepts finished blankets that are given to children ranging in ages from a few months old to 18 years. 

As one of its four core values, social responsibility, which includes giving back to the community, is not new to Baylis. The company has a group of employee volunteers, including Amanda, who make up For the Children (FTC), a charitable group which aims to improve the lives of children around the world through various initiatives.

“For members of FTC, looking for opportunities to support children has become ingrained in our day-to-day,” said Amanda. “Project Linus was a natural fit.”

The Yarncraft Club was inspired to contribute to Project Linus by the experience of two other Baylis colleagues. Jacob Oldham, the son of Baylis staff Research and Development Engineers Andrew and Lorraine Oldham, was born prematurely and has been in and out of the hospital since his birth.

“Jacob received a couple of blankets through Project Linus while he was staying at the hospital,” said Lorraine. “Every time we’ve gotten a blanket, our hearts were warmed knowing that a complete stranger would care to take the time to do this for us.”

Amanda and her Yarncraft Club cofounders — Regulatory and Scientific Affairs Team Leader, May Tsai, and Regulatory and Scientific Affairs Project Leader, Linda Wu — are currently teaching new club members how to crochet easy-to-make granny squares that will be combined to create two large-sized blankets so that all members, regardless of skill level, are able to contribute to the initiative. By the end of this summer, the Yarncraft Club will have created a half dozen handmade blankets to donate to Project Linus.

Whether it is developing innovative solutions to patient care or providing a blanket to a child in need, improving the lives of people around the world is at the heart of the Baylis culture.

 

PRM-00334 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2018. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States and/or other countries. All other trademarks are the property of their respective owners.


1 Project Linus, 2018: http://www.projectlinus.org/about

Baylis Launches New Website Featuring a Medical Education Hub

Date:

Baylis Launches New Website Featuring a Medical Education Hub

TORONTO, MAY 23, 2018 – Baylis Medical is proud to announce the launch of its new, cutting-edge website featuring a new medical education hub designed to support physicians as they navigate the healthcare industry’s evolving landscape.

The hub facilitates registration to the company’s leading-edge education programs, including hands-on training and one-on-one workshops delivered by world-class faculty. Additionally, it contains materials designed to keep physicians apprised of evolving clinical solutions, allowing them to deliver innovative patient care.

The new website also includes product pages that allow customers to virtually experience Baylis Medical’s line of products, and effortlessly transition to physical demonstrations at the click of a button. Customers will also have a wide array of clinical and scientific evidence as well as health economics information behind the company’s products available right at their fingertips.

“The redesigned website is a reflection of our deep commitment to customer service excellence and technological leadership,” said Thomas Chavez, Vice President Global Sales - Cardiology at Baylis Medical. “It is designed to allow new and existing customers to explore the broad range of innovative clinical solutions we offer to facilitate the delivery of therapies and improve the lives of patients around the world.”

To explore the new Baylis website, visit: www.baylismedical.com.

 

About Baylis Medical Company Inc.

Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spine. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK), and Munich (Germany). For more information, visit www.baylismedical.com

 

Media Contact

Elissa Hanna

Corporate Communications Manager

Baylis Medical Company

media@baylismedical.com

www.baylismedical.com 

 

PRM-00328 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2018. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States and/or other countries. All other trademarks are the property of their respective owners.

NRG® Transseptal Needle Associated with a 40% Lower Risk of Silent Cerebral Embolism

Date:

NRG® Transseptal Needle Associated with a 40% Lower Risk of Silent Cerebral Embolism

TORONTO, MAY 8, 2018 – A recent study published in Heart and Vessels has found that the use of the Baylis Medical NRG® radiofrequency (RF) Transseptal Needle for transseptal punctures was linked to a 40% lower incidence of silent acute cerebral embolism in atrial fibrillation (AF) ablation procedure patients.1

The study publication follows a consensus statement recently revised by Heart Rhythm Society and other international societies which suggests that, though the long-term impact of silent cerebral embolism needs investigation, physicians should take the necessary measures to avoid it.2 These are the first study results to find that a lower incidence could be associated with the type of transseptal needle chosen for ablation procedures.

The study compared the post-procedural MRI scans of 232 patients where AF ablation was done using either the NRG® needle or a mechanical needle. Authors suggest there were two differences between the procedures that may contribute to lower risk of silent cerebral embolism.

Advancing the sharp tip of a mechanical needle through a plastic sheath and dilator often creates plastic particles, which, if entering the bloodstream, may result in embolic material being transferred into the patient’s body. The blunt-tipped RF needle does not produce this skiving effect.

In addition, the study showed a 14-minute shorter mean procedure time when using the NRG® needle, which, as per the authors, could contribute to the lower incidence of silent cerebral embolism. The study authors also suggest the shorter procedure time could lead to cost efficiencies for electrophysiology labs.

“These study findings join the large body of evidence which confirms that using the NRG needle will result in a more predictable procedure and outcome for physicians,” said Gareth Davies, Ph.D., Research and Development Manager at Baylis Medical. “This is part of our larger focus on continually identifying the challenges faced by physicians in order to develop innovative solutions to meet the needs of their patients.”

The research findings were published in April 2018.

About Baylis Medical Company Inc.

Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spine. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK), and Munich (Germany). For more information, visit www.baylismedical.com

 

Media Contact

 Elissa Hanna

Corporate Communications Manager

Baylis Medical Company

ehanna@baylismedical.com

www.baylismedical.com 

 

PRM-00320 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2018. NRG and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.



1 Tokuda et al. Radiofrequency Needle for Transseptal Puncture is associated with Lower Incidence of Thromboembolism during Catheter Ablation of Atrial Fibrillation: Propensity score-matched analysis. Heart and Vessels. 10 April 2018. [Epub ahead of print]

2 Calkins et al.  2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017 Oct;14(10):e275-e444.

Government of Ontario Investing in New Baylis Medical Innovation Centre

Government of Ontario Investing in New Baylis Medical Innovation Centre

Date:

Government of Ontario Investing in New Baylis Medical Innovation Centre


TORONTO, APRIL 11, 2018 - Baylis Medical Company is partnering with the Government of Ontario to open a state-of-the-art Baylis Medical Innovation Centre. The new facility, located in Mississauga, Canada, will allow the company to advance its research and development (R&D) efforts, and significantly grow its product line and workforce.

The funding will support Baylis Medical as it expands its product offerings through new product lines that will advance multiple fields of medicine, such as interventional cardiology and spine. The funding also allows Baylis Medical to expand its reach into new international markets.

"As heart disease is the number one cause of death in the world,1 our focus is on constantly innovating new clinical solutions that add value to health care systems," said Neil Godara, Baylis Medical's Director of R&D. "We are pleased to have the province's support as we take these next critical steps in putting leading-edge technology in the hands of more physicians."

The grant is awarded through the provincial government's Jobs and Prosperity Fund (JPF), which supports Ontario-based businesses making significant contributions to the provincial and global economies.

"We're pleased to make this investment not only for the many good jobs it supports but for the lives it improves. There are few of us who are not touched in some way by heart disease, and applying Ontario innovation to solutions that will help more people live healthier lives is a great way we can make a difference," said the Honourable Steven Del Duca, Ontario's Minister of Economic Development and Growth.

Kris Shah, President of Baylis Medical, sees the announcement as a pivotal moment in the company's trajectory to realizing its long-term growth strategy: "Establishing the Baylis Medical Innovation Centre will maximize our ability to build a healthy product pipeline and globally increase patient-access. We are thrilled to be making this expansion in Ontario, with the support of our government."

"The Baylis Medical expansion is excellent news for Mississauga, which will benefit from the added jobs and increased recognition as an international innovation powerhouse. I am pleased to see our government continue its support of companies like Baylis Medical," said Amrit Mangat, Member of Provincial Parliament for Mississauga-Brampton South.

The Baylis Medical Innovation Centre is slated to officially open later this year.

About Baylis Medical Company Inc.
Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spine. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK), and Munich (Germany). For more information, visit www.baylismedical.com

Media Contact
Elissa Hanna
Corporate Communications Manager
Baylis Medical Company
ehanna@baylismedical.com
www.baylismedical.com 

PRM-00316 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2018. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States and/or other countries.

1 Source: World Health Organization, January 2017. (http://www.who.int/mediacentre/factsheets/fs310/en)

Baylis Medical Wins Best Managed Companies Award

Date:

Baylis Medical Wins Best Managed Companies Award


TORONTO, March 8, 2018Baylis Medical Company is proud to announce that it has been named a 2018 winner of Canada's Best Managed Companies, one of the country's leading business award programs honouring excellence in Canadian-owned and managed businesses. 

Established in 1993, Canada's Best Managed Companies recognizes those that demonstrate innovation in management and business practices, and sustained growth. This year, Best Managed companies were selected on the basis of having a clear strategy and vision, investment in capability and commitment to talent.

Behind Baylis Medical's success is a long-standing culture of empowering employees across all departments to take an innovative approach to their work. The company fosters an environment focused on learning, continuous improvement and employee development. 

"We are thrilled to have won this designation," said Deb Douma, Director of Human Resources at Baylis Medical. "We operate under the deep-rooted belief that Baylis is at its best when our employees are at their best. This makes it all the more important to give them the tools and confidence to continually contribute to our ultimate goal: developing innovative solutions that improve the lives of people around the world."

This focus has resulted in rapid growth for Baylis Medical. The company is expanding its range of products to deliver added value to patients and physicians. It is also increasing its employee-base, including its sales team, as it expands into new and existing international markets. 

"Having the in-house expertise allows us to efficiently identify issues faced by physicians and their patients, and deliver innovative solutions more rapidly. Being named one of Canada's Best Managed Companies validates our employee-centric approach to business," said Kris Shah, President of Baylis Medical.

Canada's Best Managed Companies' awardees will be honoured at the annual winners' gala taking place on April 11 in Toronto.

About Canada's Best Managed Companies
Canada's Best Managed Companies continues to be the mark of excellence for Canadian-owned and managed companies with revenues over $15 million. Every year since the launch of the program in 1993, hundreds of entrepreneurial companies have competed for this designation in a rigorous and independent process that evaluates their management skills and practices. The awards are granted on four levels: 1) Canada's Best Managed Companies new winner (one of the new winners selected each year); 2) Canada's Best Managed Companies winner (award recipients that have re-applied and successfully retained their Best Managed designation for two additional years, subject to annual operational and financial review); 3) Gold Standard winner (after three consecutive years of maintaining their Best Managed status, these winners have demonstrated their commitment to the program and successfully retained their award for 4-6 consecutive years); 4) Platinum Club member (winners that have maintained their Best Managed status for seven years or more). Program sponsors are Deloitte, CIBC, Canadian Business, Smith School of Business, TMX Group and MacKay CEO Forums. For further information, visit www.bestmanagedcompanies.ca.

About Baylis Medical Company Inc.
Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK), and Munich (Germany). For more information, visit www.baylismedical.com. 

Media Contact
Elissa Hanna
Corporate Communications Manager
Baylis Medical Company
ehanna@baylismedical.com
www.baylismedical.com


PRM-00305 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2018. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States and/or other countries. All other trademarks are the property of their respective owners.


Baylis Medical embraces advanced manufacturing with opening of state-of-the-art lab

Baylis Medical embraces advanced manufacturing with opening of state-of-the-art lab

Date:

Baylis Medical embraces advanced manufacturing with opening of state-of-the-art lab

TORONTO, January 22, 2018—Baylis Medical Company Inc., a global medical device company, has taken the next pivotal step in its global expansion strategy with the official opening of a new state-of-the art laboratory in Mississauga, Ontario. The new extrusion lab will allow the company to expand its capabilities and capacity to design, develop, manufacture and commercialize cutting-edge medical device technologies that will advance multiple fields of medical practice, including cardiology, radiology and spinal procedures.

The announcement represents a significant step in Baylis Medical’s plan to rapidly develop innovative products by bringing more capabilities in-house. Previously, the extrusion of plastic tubes used in Baylis devices was done outside of Canada, resulting in higher costs and longer production cycles.
 
“Bringing this capability in-house means we can shorten our development cycle, better control our production process and greatly improve our product design process,” says Kris Shah, President of Baylis Medical. “It shrinks our production time from about two months to less than 48 hours, which allows us to test even more design ideas, all while accelerating the production of both new and existing products.”

Baylis Medical has hired additional technical staff to support this expansion. The company is also expanding its workforce to support the production of new product lines and reach new international markets.
 
Baylis Medical was honoured to have several dignitaries attend the grand opening of its extrusion lab at 2775 Matheson Blvd. East, including the Honourable Reza Moridi, Ontario Minister of Innovation, Research and Science; Member of Provincial Parliament for Mississauga-Brampton South, Amrit Mangat; and Mayor of Mississauga, Bonnie Crombie.

Baylis Medical’s expansion was supported by investments from the Government of Canada through the Federal Economic and Development Agency for Southern Ontario (FedDev Ontario)’s Advanced Manufacturing Fund and the Ontario government through the Jobs and Prosperity Fund.
 
“Our Government is committed to helping Canadian companies fuel innovation, expand globally and create highly-skilled jobs that will ultimately strengthen our economy. Our investment in Baylis Medical is one way we are highlighting the skilled talent that is key to strengthening Canada’s global standing as a competitive and innovation nation,” says Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for FedDev Ontario.

“Baylis Medical is another great example of why Ontario is, and will remain, a leader in the innovation and knowledge economy. The Ontario government is proud to support homegrown successes that are creating jobs in Ontario and expanding sales abroad, particularly in the important field of medical devices which help improve the quality of lives for patients here in Ontario and around the world,” says Reza Moridi, Ontario’s Minister of Research, Innovation and Science.

Shah says the company’s expanded capability reinforces its commitment to “put patients first” by developing innovative medical devices, prototyping and manufacturing in-house and selling and distributing globally.

“Today’s grand opening signals a pivotal step in our company’s Vision 2020 plan, which includes building a healthy pipeline of new and innovative products and expanding our market globally,” says Shah. “It also strengthens our efforts to become a vertically integrated company with the in-house expertise needed to rapidly take an innovation from its raw material state to a manufactured device, including all the development and commercialization steps in between. We are now well-positioned to provide even more innovative and clinically relevant solutions that address real-world challenges.”

About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact:
Elissa Hanna
Corporate Communications Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 527
ehanna@baylismedical.com
www.baylismedical.com

PRM—00292 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2018. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States and/or other countries.

OHSU patient first to receive new technique to reduce high blood pressure in the liver

Date:

OHSU patient first to receive new technique to reduce high blood pressure in the liver


TORONTO, ONTARIO/PORTLAND, OREGON, December 19, 2017—Physicians in Portland, Oregon have successfully demonstrated a way to deliver potentially life-saving procedures to patients with cirrhosis of the liver. The medical team used an innovative radiofrequency (RF) device from Baylis Medical Company Inc. to open a channel, or shunt, through the hard cirrhotic tissue of the liver with minimal trauma to surrounding tissue.


The procedure, known as transjugular intrahepatic portosystemic shunt or TIPS for short, is used to treat portal hypertension, a common side effect of chronic cirrhosis that can frequently lead to life-threatening bleeding in the intestines and esophagus and fluid buildup in the abdomen. TIPS creates a new pathway that allows blood to flow better, easing pressure on enlarged veins in the stomach, esophagus, intestines and liver. The procedure is used on between 10,000 and 12,000 patients annually in the United States.


Traditionally, TIPS uses a sharp-tipped needle to mechanically puncture the tough liver tissue. Repeated attempts to cut through the liver tissue are occasionally needed which increases surgery time and the risk of damage to the surrounding tissue. Longer surgery times also means extended use of fluoroscopic imaging which results in higher radiation doses to patients and staff.


Dr. Khashayar Farsad, an interventional radiologist at OHSU, is leading a clinical study involving 10 patients to evaluate a new technique using the Baylis PowerWire® RF Guidewire. A patient at OHSU recently became the first person in the world to undergo the TIPS procedure using the PowerWire RF Guidewire.


The PowerWire RF Guidewire uses a short and highly focused RF energy pulse to cut through the tissue. Dr. Farsad is studying whether the device enables a puncture that is more controlled and predictable.


“We are pleased to be making our innovative PowerWire RF guidewire technology available to OHSU for such an important study,” says Kris Shah, President of Baylis Medical. “Baylis is committed to working with physicians everywhere to improve patient care by overcoming technical or clinical challenges. Peer-reviewed scientific studies, as well as physician feedback, have repeatedly demonstrated that Baylis devices provide clinically relevant solutions that are effective and provide improved patient outcomes.”


OHSU is the birthplace of interventional radiology, or minimally-invasive image guided procedures.  Dr. Josef Rosch, the founding director of what is now OHSU’s Charles T. Dotter Department of Interventional Radiology, pioneered the TIPS procedure in 1969.


About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact:
Ron Gonzales
Global Product Manager
Baylis Medical Company
Tel: 905.602.4875 
rgonzalez@baylismedical.com 
www.baylismedical.com

PRM-00283 EN J-1,2,3 V-1© Copyright Baylis Medical Company Inc., 2017. The Baylis Medical logo and PowerWire are trademarks or registered trademarks of Baylis Medical Company Inc. in the United States and/or other countries. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. Caution : Federal Law (USA) restricts the sale of these devices to or by the order of a physician. Patents Pending and/or issued.

The device referred to in this press release is cleared in the US to cut and/or coagulate soft tissue.
European doctors learn to access the heart from any approach with Baylis devices and expanded training program

European doctors learn to access the heart from any approach with Baylis devices and expanded training program

Date:

FOR IMMEDIATE RELEASE

European doctors learn to access the heart from any approach with Baylis devices and expanded training program


 
TORONTO, November 21, 2017— Baylis Medical Company Inc. has launched a hands-on workshop in Europe that will train cardiologists on innovative tools that enable access to the heart from any approach. This includes a growing number of procedures that require physicians to use major veins that feed into the heart from above – something the Baylis Medical SupraCross® RF System enables with ease.


Such alternate pathways offer a minimally invasive way to deliver life-saving treatments. Prior to the development of these tools, open heart surgery was the only option available for many high-risk patients.


Following its initial launch in Toronto, Canada, the SupraCross® Workshop has now expanded to Europe, a growing market for this one-of-a-kind technology. The program offers specialized training on the use of the Baylis Medical SupraCross RF System to interventional cardiologists – specialized physicians who provide catheter-based treatment of various heart diseases. 
“The SupraCross workshop was excellent,” says Dr. Zachary Whinnett, a consultant cardiologist and electrophysiologist at Hammersmith Hospital, London UK, who participated in a recent Baylis training workshop in Amsterdam. “The superb hands-on experience with these advanced tools made superior access to the left atrium easy.”


Baylis Medical’s SupraCross RF System includes a steerable sheath and flexible radiofrequency wire that were designed to achieve controlled and precise transseptal access to the left side of the heart from any approach, including from above the heart.  For example, these dedicated tools make it easier for physicians to place a pacemaker lead into the left heart in cases where traditional cardiac resynchronization therapy fails. 


“These tools are also used for accessing the heart from the subclavian vein or internal jugular vein above the heart in cases where the lower femoral vein is blocked or does not otherwise have a continuous pathway to the heart,” says Chris Bermingham, Team Leader, Clinical Education at Baylis. “This is a technically challenging procedure for even the most skilled physician, unless you have the right tools.”


“Baylis is committed to developing innovative solutions that help all patients, particularly those for whom no other medical options are available,” says Kris Shah, President of Baylis Medical. “That’s why we developed the SupraCross system, and why we are expanding our specialized training program to Europe. We know the importance of offering best-in-class clinical support to physicians who must stay abreast of a constantly evolving medical field.”


About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 


Media Contacts:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com


PRM-00273 EN J-1,2,3 V-1 © Copyright Baylis Medical Company Inc., 2017. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. SupraCross and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc.in the USA and/or other countries. Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.

Baylis Medical’s Kris Shah appointed to AdvaMed Accel Board of Directors

Baylis Medical’s Kris Shah appointed to AdvaMed Accel Board of Directors

Date:

FOR IMMEDIATE RELEASE

Baylis Medical’s Kris Shah appointed to AdvaMed Accel Board of Directors

 
Washington, DC, October 25, 2017— Baylis Medical Company, a leading developer, manufacturer, and supplier of state-of-the-art interventional cardiology products, has announced that President and co-Founder Kris Shah has been named to the Advanced Medical Technology Association's (AdvaMed) Accel Board of Directors.


“I am honoured to be appointed to the AdvaMed Accel Board and look forward to working with this distinguished group of professionals to advance medical innovations that result in healthier lives and healthier economics around the world,” said Mr. Shah. “I am particularly pleased to be joining an association that shares Baylis Medical’s adherence to the highest ethical standards and commitment for improving patients’ lives.”


“We are pleased to have Kris joining our Accel Board of Directors,” said Ashley Wittorf, Executive Director, AdvaMed Accel. “His business, engineering and commercialization experience bring a wealth of expertise to the Accel Board. In addition, his insight into international markets will be invaluable as we address the unique overseas challenges facing smaller medtech companies."


About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 


About AdvaMed Accel
AdvaMed Accel is the division within AdvaMed dedicated to addressing the unique needs and challenges of smaller medical device and diagnostics manufacturers – the lifeblood of the medical technology industry. The only organization of its kind focusing specifically on the needs of the medtech industry’s emerging growth companies, AdvaMed Accel works to create a policy environment more conducive to capital formation and innovation. For more information, visit www.advamedaccel.org.


Media Contact:

Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com


PRM—00266 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2017.
Baylis Medical and Siemens Healthineers co-sponsor physician training for state-of-the art, minimally invasive heart procedure

Baylis Medical and Siemens Healthineers co-sponsor physician training for state-of-the art, minimally invasive heart procedure

Date:

FOR IMMEDIATE RELEASE

Baylis Medical and Siemens Healthineers co-sponsor physician training for state-of-the art, minimally invasive heart procedure


TORONTO, October 17, 2017—Baylis Medical Company Inc. and Siemens Healthineers are co-sponsoring a first-of-its kind training program aimed at helping cardiologists perform a complex procedure that is quickly becoming the gold standard for treating patients with atrial fibrillation and other structural heart diseases.


The two companies are working with a network of highly respected physicians to offer the Baylis Education Hands-On Transseptal Course. This hands-on training program was launched in response to the growing need for minimally invasive procedures that require access to the left side of the heart. For example, a transseptal puncture through the septum is a standard procedure for accessing the left atrium. 


“There has been a huge growth in left-side structural procedures which all require very precise transseptal access, yet many interventional cardiologists and cardiac surgeons haven’t had the opportunity to learn transseptal techniques,” says instructor Dr. Brijeshwar Maini, interventional cardiologist and regional medical director of transcatheter therapies for Tenet Healthcare's Florida Region. “Our first course got very positive feedback from physicians. They recognize the importance in gaining experience with the best available tools to ensure the best possible outcomes for their patients.” 


Interventional cardiologists – specialized physicians who provide catheter-based treatment of various heart diseases – have previously used a sharp mechanical needle to access the left side of the heart, which has been demonstrated in comparative clinical studies to be more time-consuming and have a higher risk of complications, such as cardiac tamponade, relative to using a radiofrequency needle. Procedural complications may result in longer hospital stays and higher per-patient costs. Published studies have found that the Baylis Radiofrequency NRG® Transseptal Needle Transseptal RF solution, which uses a short and highly focused RF energy pulse, allows a puncture that is more predictable and has the potential to minimize complications.


The combination of growing medical need coupled with the availability of smaller and more sophisticated cardiac implants is making catheter-based procedures more common. The new educational course offered by Baylis and Siemens Healthineers provides interventional cardiologists and surgeons with the skills they need to use more high-tech tools that provide greater precision and less risk in accessing the left atrium. The tools in this course include Baylis’ NRG® Transseptal Needle and Siemens Healthineers ACUSON SC2000™ PRIME ultrasound system. 


“Patients suffering with atrial fibrillation or structural heart disease traditionally had to undergo high-risk open-heart surgeries,” says Kris Shah, President of Baylis Medical. “Today, state-of-the-art technologies like the Baylis RF Transseptal solution enable targeted and precise access to the left atrium. Such minimally invasive procedures typically result in lower risk to the patient, less trauma and a faster recovery.”


Interventional cardiologists and cardiac surgeons are also increasingly relying on visualization tools to accurately guide catheters and implants within the beating heart. 


“We are pleased to join with Baylis Medical in co-sponsoring training in such a rapidly growing medical segment where precise guidance is key,” says Peter Pellerito, Senior Vice President, Ultrasound North America, Siemens Healthineers. “Siemens Healthineers ACUSON SC2000 PRIME TEE and ICE tools offer ultrasound images that help make complex transseptal structural heart procedures straightforward. Physicians attending the course are able to use tools such as real-time septal guidance for more precise septal crossing and better outcomes. As more physicians gain experience in interpreting these images, we could see these innovative procedures replacing the majority of open-heart surgeries in the years ahead.”


Baylis and Siemens Healthineers sponsored the first joint course this past spring in Atlanta, GA. Based on positive feedback from participants, the companies partnered to offer the course in other U.S. cities. 


About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 


About Siemens Healthineers
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today's dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers. In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and profit of over €2.3 billion and has about 46,000 employees worldwide. Further information is available on the Internet at www.siemens.com/healthineers.


Media Contacts:

Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com

Jeff Bell
Senior Manager, Media Relations
Siemens Healthineers
Tel: (484) 868-8346
jeffrey.t.bell@siemens-healthineers.com 
www.siemens.com/healthineers

PRM—00255 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2017. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.  The Baylis Medical logo and NRG are trademarks or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries.  Other trademarks are property of their respective owners.

References:
 Hsu JC, Badhwar N, Gerstenfeld EP, Lee RJ, Mandyam MC, Dewland TA, Imburgia KE, Hoffmayer KS, Vedantham V, Lee BK, Tseng ZH, Scheinman MM, Olgin JE, Marcus GM. Randomized trial of conventional transseptal needle versus radiofrequency energy needle puncture for left atrial access (the TRAVERSE-LA study). J Am Heart Assoc. 2013 Sep 17;2(5): e000428.
Winkle RA, Mead RH, Engel G, Patrawala RA. The use of a radiofrequency needle improves the safety and efficacy of transseptal puncture for atrial fibrillation ablation. Heart Rhythm. 2011 Sep;8(9):1411-5.

IIbid

Baylis Medical teams with national Centre of Excellence to improve the lives of people with atrial fibrillation

Baylis Medical teams with national Centre of Excellence to improve the lives of people with atrial fibrillation

Date:

Baylis Medical teams with national Centre of Excellence to improve the lives of people with atrial fibrillation

More physicians will soon be evaluating an innovative radio frequency (RF) needle developed by Baylis Medical Company Inc. as part of a cross-Canada clinical trial in people with atrial fibrillation (AF). It is the most common heart arrhythmia abnormality and accounts for the majority of arrhythmia-related emergency room visits and hospital admissions.
Previous studies have demonstrated that the RF needle can be faster, safer and more effective than a mechanical needle for unrelated procedures.  Positive results from the CANet study would complement and expand this growing body of evidence.

The 150-patient, multi-centre randomized controlled trial is being sponsored by the Cardiac Arrhythmia Network of Canada (CANet), a national research network that brings together health care professionals, academia, government, industry, not-for-profit organizations, and patients to evaluate and put into practice innovative technologies that improve patient care. The study is one of several CANet-supported projects aimed at reducing AF-related emergency department visits and hospitalization, and the latest in a series of such projects in which Baylis has collaborated.

“Baylis is excited to be partnering once again with CANet, which shares our passion for improving patient care and working with hospitals to facilitate the adoption of safe and effective technologies,” says Kris Shah, President of Baylis Medical, which is providing local physicians with its commercial product and training on how to use it. “Access to CANet’s leading-edge network of investigators allows us to introduce our therapies to even more hospitals, and bring relief to patients, faster.”

Dr. Jason Andrade, the study’s principle investigator, says “Given the number of patients suffering with atrial fibrillation, and the significant healthcare costs associated with managing it, there is a critical need for innovative minimally invasive cardiac procedures that improve patient outcomes without increasing healthcare costs”. 

“In August, Dr. Peter Leong-Sit at London Health Sciences became the first physician in this trial to use the Baylis left atrial access equipment, which included the Baylis RF needle, and the surgery was a success,” says Dr. Andrade, Director of Electrophysiology at Vancouver General Hospital. 

The clinical study is evaluating two different technologies for accessing the left atrium, which is required for AF ablation procedures as well as the treatment of certain structural heart diseases. One technology is Baylis’ NRG® Transseptal Needle, a blunt-tipped electrode that delivers a short and a highly focused RF energy pulse, allowing a puncture that is more predictable and has the potential to minimize complications. Researchers will also evaluate a procedure where heart rhythm specialists push a sharp, mechanical needle to puncture the tissue. This traditional technique has been demonstrated in comparative clinical studies to be more time-consuming and to lead to complications, such as cardiac tamponade. Procedural complications may result in longer hospital stays and higher per-patient costs.

This will be the first study evaluating the use of Baylis’ Transseptal equipment during a special type of atrial fibrillation procedure that uses a cryoablation balloon catheter to ablate tiny areas in the heart that cause rapid and irregular heartbeats.

Dr. Allan Skanes, CANet’s AF Theme Leader and Director of the London Heart Rhythm Program, has described the Baylis technology as a “slicker and more useful version of the old sharp needle technique” that gives physicians greater control and precision in crossing the septum. Baylis’ product is designed and manufactured in Canada, and cleared for use in several jurisdictions, including Canada, the U.S., EU and Japan.

CANet’s Scientific Director and CEO Dr. Anthony Tang says the study serves as an example of how clinicians and industry partners can work together to improve patient outcomes and enhance productivity in the healthcare system.

“We hope from this study to demonstrate that by treating patients earlier in their disease, we can potentially reduce the risk of stroke and other heart problems from occurring later. The goal is to see this surgical intervention become a frontline treatment for more patients in Canada, and around the world.” says Dr. Tang.

The early release of Baylis’ NRG® Transseptal Needle was made possible, in part, by a repayable matching contribution of $15.2 million from the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) through its Advanced Manufacturing Fund. 

“We are pleased to match Baylis’ investment to accelerate the development and commercialization of the first-in-Canada medical devices that will be used by doctors during heart procedures,” says the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development and Minister responsible for FedDev Ontario. “Such innovative and transformative products are expanding international markets for made-in-Canada technologies that have a positive impact on patients around the world.”

About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com

About CANet:
The Cardiac Arrhythmia Network of Canada (CANet) is a not-for-profit organization dedicated to transforming Canada’s arrhythmia health care system through integrated trans-disciplinary research and development. The network’s strategy is to invent, prove, and implement innovative solutions to enable patients to take ownership and co-manage their arrhythmia health. CANet is funded by the federal government’s Networks of Centres of Excellence (NCE), Canada’s flagship science and technology program.

References:
IJason G Andrade, MD, Marc Dubuc, MD, Peter G Guerra, MD, Laurent Macle, MD, Lena Rivard, MD, Denis Roy, MD, Mario Talajic, MD, Bernard Thibault, MD, and Paul Khairy, MD, PhD. Cryoballoon Ablation for Atrial Fibrillation, Indian Pacing Electrophysiology Journal. 2012. Mar-Apr; 12(2): 39–53.

IIWinkle RA, Mead RH, Engel G, Patrawala RA. The use of a radiofrequency needle improves the safety and efficacy of transseptal puncture for atrial fibrillation ablation. Heart Rhythm. 2011 Sep;8(9):1411-5.

Hsu JC, Badhwar N, Gerstenfeld EP, Lee RJ, Mandyam MC, Dewland TA, Imburgia KE, Hoffmayer KS, Vedantham V, Lee BK, Tseng ZH, Scheinman MM, Olgin JE, Marcus GM. Randomized trial of conventional transseptal needle versus radiofrequency energy needle puncture for left atrial access (the TRAVERSE-LA study). J Am Heart Assoc. 2013 Sep 17;2(5): e000428.

IIIIbid

IVIbid

PRM-00245 EN J-1,2,3 V-2 © Baylis Medical Company Inc., 2017. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. NRG and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use. Patents pending and/or issued.
Baylis Medical strengthens global expansion plans with senior hire

Baylis Medical strengthens global expansion plans with senior hire

Date:

For Immediate Release

BAYLIS MEDICAL STRENGTHENS GLOBAL EXPANSION PLANS WITH SENIOR HIRE


TORONTO, August 23, 2017—Baylis Medical Company Inc. has recruited a seasoned industry executive to lead a growing global sales team to fast-track the company’s expansion into existing and new international markets. Baylis, a leading developer, manufacturer, and supplier of state-of-the-art interventional cardiology products, is pleased to announce that Thomas Chavez has joined the company in the new position of Global Vice President of Sales, Cardiology.

“Thomas’ appointment will be a key driver in accelerating our global commercialization strategy,” says Kris Shah, President of Baylis Medical. “His extensive international sales experience combined with his strategic insight into the medical device market will deepen our relationships with existing customers in Canada, Japan, Europe and United States, while opening new opportunities in China, elsewhere in Asia and the Middle East. With this appointment, Baylis is on track to fulfil its mission to be a world leader in the development and distribution of innovative, high-technology products that will improve the lives of people around the world.”
 
Chavez’s responsibilities include executing a dynamic global marketing strategy, managing key distributor relationships, and mentoring and growing a team of sales professionals beyond existing markets in the U.S., Canada and Europe. He will focus on expanding the market for Baylis’ existing line of medical products, as well as opening new markets for products currently in the development pipeline. Baylis has sales offices in Toronto and Montreal (Canada), Boston (U.S.), London (U.K.) and Munich (Germany). 

“I’m excited to join a company with such a passion for patient care,” says Chavez, who will work from both Austin, Texas and Toronto. “That commitment nurtures a culture within our organization that is nimble, innovative and socially responsible. Baylis’ focus on solving disease state issues means the technologies produced are both clinically relevant and economically sound which provides value to the patient and customer alike.”

Chavez has 30 years of medical device experience with over half of that time at the executive level running large-scale sales, marketing and corporate account organizations. For over 15 years he worked at St. Jude Medical, a global medical device company headquartered near Saint Paul, Minnesota, where he held a variety of executive positions, including Senior Vice President. Most recently, he was Vice President for the Americas at Smith Medical and prior to that he was with Zimmer Orthopedics. His experience extends across broad categories and disease states, including electrophysiology, cardiac rhythm management, cardiac valves, orthopedics and drug delivery.  

“Many of the organizations I have worked with compete in similar or adjacent markets, and developed innovative and successful solutions to a changing healthcare system. I look forward to applying that experience to ensure that even more people will benefit from Baylis Medical’s innovations,” says Chavez.

“Thomas is a perfect fit for our company. He has deep sales and marketing experience in the field of cardiology, particularly cardiac electrophysiology and structural heart products,” adds Shah. “He is also a good fit with the Baylis culture. He will play a strategic role in helping our company learn new skills, grow our team and expand our business globally.”

About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while improving the lives of people around the world. The company has offices in Montreal and Toronto (Canada), Boston (U.S.), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com

PRM-00234 EN J-1,2,3 V-1© Baylis Medical Company Inc., 2017. The Baylis Medical logo is a registered trademark of Baylis Medical Company Inc. in the USA and/or other countries. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.

St. Michael’s cardiologist performs successful world first, using a novel Canadian-invented device

Date:

For Immediate Release

ST. MICHAEL’S CARDIOLOGIST PERFORMS SUCCESSFUL WORLD FIRST, USING A NOVEL CANADIAN-INVENTED DEVICE


TORONTO, May 24, 2017—When Dr. Neil Fam examined his 86-year-old patient with severe mitral regurgitation—a condition in which the blood flows backward into the heart after it contracts—his options for treating her were limited.

Because of her age and overall health, Ortensia Aceti of Sault Ste. Marie, Ont., was not a good candidate for surgery to repair her mitral valve, the flap between the two left chambers of her heart. She had been in and out of hospital with heart failure, and medication was no longer controlling her symptoms.

Instead, Dr. Fam decided on a catheter-based treatment to guide a MitraClip® device to the heart and clamp the leaky valve. The catheter would usually be inserted through the femoral vein in the leg, but her vein was blocked.

“We were locked out, blocked from accessing her heart,” said Dr. Fam, an interventional cardiologist and director of the Cardiac Intensive Care Unit of St. Michael’s Hospital in Toronto.

Dr. Fam recalled a conversation he had about a year previously with Baylis Medical Company, Inc., a Canadian supplier of high-tech cardiology equipment, about their SupraCross® RF Solution, which includes a steerable sheath and radiofrequency wire that were designed to achieve transseptal access to the heart from alternative approaches. These devices can enter the body through the jugular vein in the neck, enabling access to the leaky valve despite the blockage in her leg.

For the first time in the world, Dr. Fam successfully used the SupraCross® RF Solution to guide a MitraClip® device through the jugular vein into the heart and successfully repair a leaking mitral valve.

Dr. Fam said this was possible, despite the awkward angle of the jugular vein in relation to the heart, because the tip of the sheath is steerable and the wire is equipped to deliver radiofrequency energy to puncture the septum of the heart. This allows the physician to position the system appropriately from this challenging angle, and puncture the septum in a precise and controlled manner without using excessive force. The septum is the dividing wall between the left and right sides of the heart and it’s the last barrier to getting to the mitral valve, which sits between the left ventricle and the left atrium.

Dr. Fam said that Mrs. Aceti had no complications and that her condition improved, allowing her to be discharged to her home. At a follow-up appointment, the patient was doing well with no further heart failure.

Sue Carlucci, one of Mrs. Aceti’s three daughters, said that Dr. Fam explained the novel procedure to the family carefully in advance.

“If Dr. Fam hadn’t suggested this procedure, we probably would have lost our mom,” she said.

“He’s our angel,” she said, referring to St. Michael’s nickname, the Urban Angel.

Dr. Fam said that while this procedure would be appropriate for only selected patients, they are high-risk patients for which there may be no other treatment options.

“Given the success of this procedure, the door is open for future studies of the jugular approach for treating the mitral valve,” he said.

Dr. Fam published a report of this procedure in the journal Eurointervention on May 9.

About St. Michael’s Hospital 
St. Michael’s Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 29 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, care of the homeless and global health are among the hospital’s recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Center, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael’s Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto.

For more information, or to interview Dr. Fam please contact:
Leslie Shepherd
Manager, Media Strategy
Phone: 1-416-864-6094
shepherdl@smh.ca
St. Michael’s Hospital
Inspired Care. Inspiring Science.
 
About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures.  Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World.  The company has offices in Montreal and Toronto (Canada), Boston (USA), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 
 
Media Contact Person:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com
www.baylismedical.com
 
© Baylis Medical Company Inc., 2017. The Baylis Medical logo and SupraCross are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. All other trademarks are the property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.
Baylis Medical Broadens Medtronic Partnership With Expanded Indications For The Osteocool™ RF Ablation System

Baylis Medical Broadens Medtronic Partnership With Expanded Indications For The Osteocool™ RF Ablation System

Date:

Baylis Medical Broadens Medtronic Partnership With Expanded Indications For The Osteocool™ RF Ablation System



(Montreal, Canada, February 15, 2017)

Baylis Medical Company announces U.S. Food and Drug Administration (FDA) 510(k) indication expansion of the OsteoCool™ RF Ablation System to include coagulation and ablation of tissue in bone during surgical procedures including palliation of pain associated with metastatic lesions involving bone in patients who have failed or are not candidates for standard therapy. The OsteoCool™ System was previously indicated for use in the spine, which remains part of its intended use.  With the expanded indication, the technology may now be used for palliative treatment of metastases in all bony anatomy - such as ribs, sacrum, extremities, and hip. 


The indication expansion was cleared just one year after Medtronic acquired the OsteoCool™ technology and associated intellectual property from Baylis Medical.  Subsequently, Baylis Medical broadened the partnership in leading the pursuit of the FDA 510(k) indication expansion.

  

Metastatic bone disease has been reported to occur in 60-80% of cancer patients, most frequently among patients with primary malignancies of the breast, prostate, liver, and lung.i  More than 80% of bone metastases are found in the axial skeleton, which includes the skull, spine, and ribs.ii


The OsteoCool™ System enables minimally-invasive treatment of patients suffering from painful malignant metastases in peripheral bone, the first treatment of its kind in the U.S. The OsteoCool™ System is the only cooled radiofrequency (RF) ablation technology designed to perform optimally in bone that offers simultaneous, dual-probe capabilities – providing for procedural flexibility and predictable, customized treatment. Cooled RF ablation uses targeted radiofrequency energy to ablate metastatic malignant lesions.

 

"We're pleased to broaden our partnership with Medtronic to improve the treatment of patients suffering from painful metastases," said Kris Shah, president of Baylis Medical.  "The expansion of the OsteoCool™ System to include the ablation of malignant lesions in bone adds to our company’s track record of offering innovative clinical solutions and further enhancing patient access and treatment options.”


"Our Pain Therapies business is deeply rooted in the Medtronic Mission – which calls us to alleviate pain,” said Jeff Cambra, General Manager of the Pain Therapies Interventional business, which is part of the Restorative Therapies Group at Medtronic. “With this expanded indication, we put an important treatment option into the hands of physicians so that they can help more patients suffering from debilitating pain.”


About Baylis Medical Company

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures.  Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World.  The company has offices in Montreal and Toronto (Canada), Boston (USA), London (U.K.) and Munich (Germany).  For more information, visit www.baylismedical.com. 

Media Contact Person:

Laura Mills

Marketing Manager

Baylis Medical Company

Tel: 905.602.4875 ext. 292

lmills@baylismedical.com

www.baylismedical.com


About Medtronic

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.


i Schuleman et al. Economic Burden of Metastatic Bone Disease. American Cancer Society, 2007.

ii Nielson et al. Bone Metastases: Pathophysiology and Management Policy. American Society of Clinical Oncology, 1991.


PRM-00156 EN J-1,2,3 V-1 © Baylis Medical Company Inc., 2017. The Baylis Medical logo is a trademark and/or registered trademark of Baylis Medical Company Inc. in the USA and/or other countries. All other trademarks are the property of their respective owners. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.


First UK Procedures With New Left Heart Access System Enable More Treatment Options

First UK Procedures With New Left Heart Access System Enable More Treatment Options

Date:

FIRST UK PROCEDURES WITH NEW LEFT HEART ACCESS SYSTEM ENABLE MORE TREATMENT OPTIONS


 (London, UK, January 11, 2017) Baylis Medical’s SupraCross™ RF System was used for the first time in the United Kingdom to allow minimally invasive treatment of 2 patients suffering from symptomatic heart failure that would have otherwise faced open heart surgery. 

Treatment of these heart failure patients often includes cardiac resynchronization therapy (CRT), however for a significant number of patients, the conventional implant technique fails. The only other option has historically been an open surgical procedure which carries additional risks and is not well tolerated by many of these patients. Placing the pacemaker leads into the left heart through the atrial septum offers an alternative minimally invasive approach, however this has been challenging without dedicated tools. 

The SupraCross™ RF System is a novel solution for achieving transseptal access to the left side of the heart from alternative approaches. The first SupraCross™ RF System procedures have been performed by Dr. Paul R. Roberts, M.D., Consultant Cardiologist and Electrophysiologist at the Southampton General Hospital in Hampshire, England.

 “The SupraCross System represents the first dedicated tool for a controlled and effective mechanism of crossing the atrial septum from this alternative approach.” said Dr. Roberts. “This technology represents a major step forward in providing more treatment options for patients that do not have suitable conventional venous anatomy or have not responded to the conventional technique. High risk patients can now avoid major cardiothoracic surgery yet still receive all the benefits of biventricular pacing.”

One of the two patients treated described the significance of this new approach and outcome of the therapy he received from his perspective: “I am delighted that this procedure has meant that I have not had to undergo a major cardiac surgical operation, and I’m already noticing a significant improvement in symptoms with less breathlessness and chest pain.”

The system, developed and manufactured by Baylis Medical in Ontario, Canada, has helped treat many patients in Canada and the United States. After recently receiving CE Mark approval, these 2 patients mark the first outside of North America to benefit from this technology. 

About Baylis Medical Company:
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK) and Munich (Germany). For more information, visit www.baylismedical.com

Media Contact Person:
Laura Mills
Marketing Manager
Baylis Medical Company
Tel: 905.602.4875 ext. 292
lmills@baylismedical.com

About Southampton General Hospital:
Southampton General Hospital is the University Hospital Southampton NHS Foundation Trust’s largest location, with a great number of specialist services based here, ranging from neurosciences and oncology to pathology and cardiology.
Emergency and critical care is provided in the hospital’s special intensive care units, operating theatres, acute medicine unit and emergency department (A&E), as well as the dedicated eye casualty.
Southampton General also hosts outpatient clinics, diagnostic and treatment work, surgery, research, education and training, as well as providing day beds and longer stay wards for hundreds of patients.

PRM-00141 EN J-1,2,3 V-1© Baylis Medical Company Inc., 2016.  SupraCross and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries.  Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.

BAYLIS MEDICAL WINS GLOBAL TRADE AWARD

BAYLIS MEDICAL WINS GLOBAL TRADE AWARD

Date:

For immediate release 

BAYLIS MEDICAL WINS GLOBAL TRADE AWARD 


Montreal, QC – (November 16, 2016) – Baylis Medical has been honoured by the Toronto Region Board of Trade with this year’s Global Trade Award. This distinction recognizes a company with an exciting and viable trade business that is contributing to the Canadian economy by generating export-driven revenue and creating or supporting jobs. 

The award was presented during the 2016 Business Excellence Awards held on November 10th in Toronto. The annual event celebrates companies who have demonstrated exceptional growth, leadership and innovation.  

As noted by Toronto Region Board of Trade President & CEO Jan De Silva, “By successfully growing a business, our 2016 Business Excellence Award winners and nominees are creating opportunities for hundreds of thousands of Canadians. They are role models who are making Toronto one of the most competitive and sought after regions in the world.”  

Kris Shah, President of Baylis Medical Company Inc., accepted the award on behalf of Baylis. 

 “We are honoured  to have been recognized by our peers and declared winner of the 2016 Global Trade Award.” says Shah. “This award reflects the tireless focus and dedication of our highly talented staff, enabling high technology medical devices to improve the lives of patients worldwide.”  

About Baylis Medical Company Inc.: 
Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK) and Munich (Germany). For more information, visit www.baylismedical.com. 

Media Contact Person: 
Luc Desaulniers 
Senior Marketing Communications Specialist 
Baylis Medical Company 
Tel: 514-488-9801 
ldesaulniers@baylismedical.com 
www.baylismedical.com 

Baylis Medical expands its presence with a new office in Germany

Date:

For immediate release

BAYLIS MEDICAL EXPANDS ITS PRESENCE WITH NEW OFFICE IN GERMANY

Montreal, QC – (September 28, 2016) – Baylis Medical Company Inc., a leading supplier of high-technology medical devices, is pleased to announce the opening of its new office in Munich, Germany. As part of Baylis Medical’s continued expansion, the new office will serve the company’s growing European customer base. 

The addition of the Munich office complements the company’s existing offices in London, Boston, Toronto, and Montreal.

“We’re excited to continue to expand our global presence by establishing roots in Germany. This new location allows Baylis Medical to offer local support to our growing customer base. It is a testament to our continued success in Europe” said Kris Shah, President of Baylis Medical. The company plans to recruit additional members for the regional team in the near future.

“Choosing Munich as part of its strategic expansion in Europe shows that innovative companies like Baylis Medical value the outstanding position Bavaria enjoys internationally, particularly in the field of medical technologies” said Frédéric Arsenault, Project Manager Business & Technology, State of Bavaria Quebec Office.

Baylis Medical’s new office is located at the following address:

BAYLIS Medical (Deutschland) GmbH

 Landshuter Allee 8-10

80637 München

Germany


About Baylis Medical Company Inc.:

Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies to Improve the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), London (UK) and Munich (Germany). For more information, visit www.baylismedical.com.


Media Contact Person:

Luc Desaulniers

Senior Marketing Communications Specialist

Baylis Medical Company

Tel: 514-488-9801

ldesaulniers@baylismedical.com

www.baylismedical.com

 

                                                                               —30—




© Copyright Baylis Medical Company Inc., 2016. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Baylis Medical pledged $300,000 toward Waterloo University Engineering

Date:

For immediate release


MEDICAL PLEDGES $300,000 TOWARDS FUTURE INNOVATION BY UNIVERSITY OF WATERLOO ENGINEERING STUDENTS

 

(Montreal, 4 May 2016) Baylis Medical is donating $300,000 to support future innovations by University of Waterloo systems design and biomedical engineering students.

The funding will be used for the Baylis Medical Student Garage to be located in University of Waterloo’s Engineering 7 building currently under construction.

The 1,010 square foot garage, to be the largest student garage in the Engineering 7 building, will provide the biomedical engineering students with dedicated space to work on their senior year projects.

“The Baylis Medical Student Garage will be well used by our systems design and biomedical engineering students to create the next generation of medical devices,” said Pearl Sullivan, acting dean of Waterloo Engineering. “We are grateful to Baylis Medical for supporting our Educating the Engineer of the Future campaign. We are proud to name this exciting space after such an innovative company that leads the way in high-technology medical devices. We look forward to witnessing future innovations in this field by our students.”

Based on the success of the student team garages in the Faculty’s Engineering 5 building, the Baylis Medical Student Garage will provide systems design and biomedical engineering students with opportunities to create and innovate.

“Baylis is proud to be associated with one on the most innovative universities in North America. The Baylis Medical Student Garage will further the development of knowledge and resources toward educating the biomedical engineers of the future” says Kris Shah, President of Baylis Medical Company Inc. and a Waterloo Engineering graduate.

Baylis Medical’s pledge is one of the many financial contributions the company has made to the academic community.

About Baylis Medical Company:

Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (UK). For more information, visit www.baylismedical.com.

 Media Contact Person:

Luc Desaulniers
Senior Marketing Communications Specialist
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com
 
 

                                                                              —30—


© Copyright Baylis Medical Company Inc., 2016. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.


Ontario investing $4.22 million to expand Baylis Medical R&D and manufacturing operations.

Date:

For immediate release


ONTARIO INVESTING $4.22 MILLION TO EXPAND BAYLIS MEDICAL R&D AND MANUFACTURING OPERATIONS IN MISSISSAUGA



(Montreal, March 17, 2016) —Ontario is partnering with Baylis Medical Company to support an expansion project at the company’s Mississauga research and development (R&D) and manufacturing facilities, which will create 84 new jobs that will be added to the 194 current jobs.

Through the province’s Jobs and Prosperity Fund, specifically under the New Economy Stream, Ontario will provide a conditional grant of up to $4.22 million to support the company’s expansion into a new advanced facility, and its plan to almost double its exports over the course of this investment.

Expansion and additional manufacturing capabilities will help Baylis Medical reduce costs and bolster the company’s position to enable continued growth of its core business. Investments in talent will support the production of three new product lines and help the company reach new international markets, including Australia, Brazil, China and South Korea. The $32.5 million overall investment being made towards the new project will significantly increase the company’s cleanrooms and R&D spaces.

“The government’s number-one priority is growing the economy and creating jobs.” said  Hon Brad Duguid, Ontario Minister of Economic Development, Employment and Infrastructure. “The government’s support for Baylis Medical will help them expand facilities, ramp up their important research and development work and leverage new and innovative technologies. These efforts will allow Baylis Medical to strengthen their exports and significantly increase global competitiveness.” 

“Today’s announcement is great news for Mississauga. I’m delighted that our government continues to invest in our life sciences sector by supporting innovative companies like Baylis Medical that generate significant economic activity, both at home and abroad.”
— Amrit Mangat, MPP for Mississauga—Brampton South

“We are pleased to be partnering with Ontario on this expansion project. Our company has a track record for developing and commercializing advanced medical devices.” said Kris Shah, President, Baylis Medical Company. “This new facility will give us the space to increase production and hire additional resources to expand our portfolio of innovative products.  This strategic partnership will help us compete and succeed globally.”


About Baylis Medical Company:
Baylis Medical develops and markets high-technology medical devices used in the fields of electrophysiology, interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (UK). For more information, visit www.baylismedical.com.


Media Contact Person:
Luc Desaulniers, 
Senior Marketing Communications Specialist 
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com




                                                                              —30—




© Copyright Baylis Medical Company Inc., 2016. Baylis Medical Company Inc. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Baylis Medical in partnership with CANet brings new possibilities to patients suffering from cardiac arrhythmias

Date:

For immediate release


BAYLIS IN PARTNERSHIP WITH CANET BRINGS NEW POSSIBILITIES TO PATIENTS SUFFERING FROM CARDIAC ARRHYTHMIAS


(Montreal, February 15, 2016) Baylis Medical’s new streamlined transseptal system, licensed in Canada, comprised of a radiofrequency active pigtail guidewire and a steerable sheath, brings new possibilities to patients suffering from heart failure.

Dr. Jaimie Manlucu, treating physician, CANet Investigator, and member of the Arrhythmia Service at London Health Sciences in London, Ontario noted that a significant number of heart failure patients who are candidates for cardiac resynchronization therapy (CRT) often have suboptimal outcomes with conventional implant techniques.  Placing CRT pacing wires into the left heart through the atrial septum is a promising alternative approach, but can be challenging without dedicated tools.

“This innovative transseptal system from Baylis Medical is the first commercially available  apparatus that optimizes transseptal access from an alternate superior approach,” said Dr. Manlucu, “Streamlining the transseptal aspect of the implant procedure allows us to provide this therapy in a reliably safe and efficient way.”

“We are pleased to have developed this streamlined access method to the left atrium that enables physicians to deliver their therapies.” said Kris Shah, president of Baylis Medical. “Access to CANet’s leading-edge network of investigators allows us to validate our therapies and move them to the market – and bring relief to patients, faster.”

“Partnerships with Canadian companies, like Baylis Medical, are integral to developing and commercializing potentially lifesaving therapies,” said Dr. Anthony Tang, CEO and Scientific Director of CANet. “By working together we will develop cutting edge technologies and become a powerful engine of innovation for the arrhythmia field.”

These new devices developed and manufactured by Baylis Medical in Ontario, Canada were made possible in part by a repayable contribution through the Federal Economic Development Agency for Southern Ontario’s Advanced Manufacturing Fund.


About CANet:
The Cardiac Arrhythmia Network of Canada is a not-for-profit organization dedicated to transforming Canada’s arrhythmia health care system through integrated trans-disciplinary research and development. The network’s strategy is to invent, prove, and implement innovative solutions to enable patients to take ownership and co-manage their arrhythmia health. CANet is funded by the federal government's Networks of Centres of Excellence (NCE), Canada's flagship science and technology program.

About Baylis Medical Company:
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (UK). For more information, visit www.baylismedical.com.

Media Contact Person:
Luc Desaulniers, 
Communications Associate, 
Baylis Medical Company
Tel: 514-488-9801 ldesaulniers@baylismedical.com
http://www.baylismedical.com






© Copyright Baylis Medical Company Inc., 2016. Baylis Medical Company Inc. The Baylis Medical logo is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries. Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions, and instructions for use. 

CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician. 



Baylis Medical partners with Medtronic on innovative spinal tumor ablation technology.

Baylis Medical partners with Medtronic on innovative spinal tumor ablation technology.

Date:

For immediate release

BAYLIS MEDICAL PARTNERS WITH MEDTRONIC ON INNOVATIVE SPINAL TUMOR ABLATION TECHNOLOGY 


(Montreal, Canada, January 13, 2016) 

Baylis Medical Company announces a partnership with Medtronic (NYSE: MDT) to enhance patient access to a highly innovative spinal tumour ablation system which recently received U.S. Food and Drug Administration (FDA) 510(k) clearance. 

For physicians who treat patients with painful spine metastases, the OsteoCool™ RF Ablation System is the only cooled radiofrequency (RF) ablation technology that offers simultaneous, dual-probe capabilities – providing procedural flexibility and predictable, customized treatment.  Cooled RF ablation uses targeted high-frequency energy to ablate tumors.

Medtronic acquired the OsteoCool technology and associated intellectual property from Baylis Medical on December 16, 2015 and partnered with the company to further innovate the System.  Terms of the acquisition were not disclosed.

"The OsteoCool System expands our Pain Therapies portfolio,” said Julie Foster, general manager and vice president of the Pain Therapies business in the Neuromodulation division, which is part of the Restorative Therapies Group at Medtronic.  "Our customers treat patients with Kyphon® Balloon Kyphoplasty who also have painful spinal metastases.  The OsteoCool system gives physicians a way to treat that pain in a single procedure with a familiar, minimally invasive technique.” 

“We’re pleased to be partnering with Medtronic to improve the treatment of patients suffering from spinal metastases," said Kris Shah, president of Baylis Medical.  "Our company has a long, established track record of developing innovative clinical solutions.  We are excited that this partnership with Medtronic will enhance patient access to our novel spinal tumor ablation technology.”

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

About Baylis Medical Company
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (U.K.). For more information, visit www.baylismedical.com

Media Contact Person:
Luc Desaulniers, 
Communications Associate, 
Baylis Medical Company
Tel: 514-488-9801 ldesaulniers@baylismedical.com
http://www.baylismedical.com

Kyphon Balloon Kyphoplasty incorporates technology developed by Gary K. Michelson, M.D.

-30-

Medtronic OsteoCool Demonstration: Play video

Baylis Medical Company unveils its new 70,000 Sq Ft facility in Mississauga.

Date:

For immediate release

 

Baylis Medical Company unveils its new 70,000 Sq Ft facility in Mississauga.  

(Mississauga, Canada, December 7, 2015) Baylis Medical Company is proud to announce the opening of their newest research, development, and production facility in Mississauga, Ontario. The expansion into the state-of-the-art, 70,000-sq. ft. facility more than doubles the company’s cleanroom and R&D space.

“I can’t overstate the impact that this new facility will have on our core business of developing high-technology medical devices,” said Kris Shah, President of Baylis Medical. “With the increased space and resources, the opportunity for technological advancement and company growth is extraordinary. We are now better able to pursue our mission of Improving the Lives of People Around the World.” “Today’s grand opening showcases the strength of Canada’s high-tech medical sector and the future of manufacturing in southern Ontario,” stated the Honourable Navdeep Bains, Minister of Innovation, Science and Economic Development. “I look forward to seeing the continued growth of Baylis and other innovative businesses that create good quality jobs and wealth for all Canadians.” Baylis Medical Company will unveil the new facility at 2775 Matheson Blvd. East in an Opening Ceremony to be held on December 7, 2015.

The expansion, including new and improved manufacturing capabilities, was made possible, in part, by a repayable contribution from FedDev Ontario through the Advanced Manufacturing Fund.

About Baylis Medical Company

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. Our vision is to develop and market innovative medical therapies while Improving the Lives of People Around the World. The company has offices in Montreal and Toronto (Canada), Boston (USA), and London (U.K.). For more information, visit www.baylismedical.com

Media Contact Person:
Luc Desaulniers, Communications Associate,
Baylis Medical Company
Tel: 514-488-9801 ldesaulniers@baylismedical.com
http://www.baylismedical.com

Baylis Medical thrives with support of Greater Boston community; moves to larger offices

Date:

FOR IMMEDIATE RELEASE

 

Baylis Medical thrives with support of Greater Boston community; moves to larger offices

 

Burlington, Mass. (September 10, 2015) – Baylis Medical is pleased to announce their relocation to a larger office in Burlington, Mass. After its initial arrival to the Greater Boston area in 2013, Baylis Medical’s continued success has surpassed the available space allocation and was required to relocate to a new office site.

Baylis Medical’s expanding US sales force and product line has warranted this relocation. “Consequent with Baylis Medical policies, our new location includes many environmentally friendly features, and relies largely on natural daylight”. comments Marie-Claude Jacques, National Sales Manager USA.

Baylis Medical’s new office is located at the following address:

78 Blanchard Road, Suite 204

Burlington, MA 01803

 

A ribbon-cutting ceremony was held today to officially open the new facility.

 

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology, interventional radiology, and spinal procedures. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, Boston (USA) and, London (U.K.). For more information, visit www.baylismedical.com

 

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

m

Baylis Medical Expands European Reach with New Office Opening in London, UK

Date:

FOR IMMEDIATE RELEASE

Baylis Medical Expands European Reach with New Office Opening in London, UK

Watford, United Kingdom (November 24th, 2014) – Baylis Medical, a leading supplier of high-technology interventional cardiology and radiology products, is pleased to announce the official opening of its new office in Watford, UK, on the outskirts of London. The opening of the Watford office is a part of Baylis Medical’s European expansion project.

Baylis Medical’s business in Europe has grown substantially with an expanding sales force, strong distribution partnerships and the successful launch of several new products. The Watford office expansion was warranted by this growth. “The new office represents our commitment towards our continued growth in the European market through strengthened operational capabilities, enhanced technical support, and direct sales in the UK, Germany and France.” said Frank Baylis, President.

Found within the life sciences “Golden Triangle”, the new office will also bring in new opportunities for Baylis Medical. “The Golden Triangle is a hub of bio-tech activities, and we are looking forward to tapping into the local expertise as we continue to expand our presence,” noted Mr. Baylis. “We will be looking to recruit more members to our team in the near future.”

“Congratulations to Baylis Medical on the opening of its expanded office,” said Paul Witcombe, Enterprise & Innovation Manager at the Hertfordshire Local Enterprise Partnership (LEP), a regional business development firm aiding businesses to tap into the area’s key resources. “We are pleased that the company has chosen Watford as the home for its European operations. The company’s portfolio of products, ranging from cardiology to radiology, is a great addition to our life sciences community, and we are confident that Watford is the best place for Baylis Medical to continue to grow its business.”

Baylis Medical’s new office is located at the following address:
Suite 11, Building 6
Croxley Green Business Park
Watford, Hertfordshire
WD18 8YH
United Kingdom

 
About Baylis Medical
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to provide access to various parts of the cardiovascular system. The company has offices in Montreal, Toronto, Vancouver, Boston (USA) and, London (U.K.). For more information, visit www.baylismedical.com.  
 
Contact
Luc Desaulniers

Communications Associate

Baylis Medical Company

Tel: 514-488-9801

ldesaulniers@baylismedical.com

http://www.baylismedical.com

###

© Copyright Baylis Medical Company Inc., 2014 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered.

 First European Experience with Innovative Guidewire at St George’s Hospital London, UK

First European Experience with Innovative Guidewire at St George’s Hospital London, UK

Date:

FOR IMMEDIATE RELEASE

First European Experience with Innovative Guidewire at St George’s Hospital London, UK

 London, United Kingdom (July 1st, 2014) – The first cases using the ProTrack™ Pigtail Wire in Europe were performed last month at St George’s Hospital in London. The ProTrack™ Pigtail Wire is used during the transseptal procedure, a challenging minimally  invasive technique used to cross the septum of the heart.

 Dr. Riyaz Kaba, Electrophysiologist at St George’s Hospital, explains: “The ProTrack™ Pigtail Wire worked very well in our initial experience. The design combines a strong core in the body of the wire with a soft, curled tip.  The strong core provides the strength needed to cross a challenging septum, while the soft tip is atraumatic to the left atrium.”

 In certain patients, physicians are faced with highly resistant cardiac tissue. In such instances, physicians are normally required to apply strong pressure on catheters and guidewires, which increases the risk of inadvertent perforation. The ProTrack™ Pigtail Wire is designed to minimize this risk by providing more control.  

 The transseptal procedure is commonly part of atrial fibrillation ablation procedures and other emerging cardiac interventions, such as left atrial appendage occlusion and mitral valve repair. It is a challenging and specialized technique used to place treatment catheters into to the left atrium of the heart.

 The ProTrack™ Pigtail Wire, designed specifically for the transseptal procedure, incorporates a stiff body with a soft curling pigtail-like tip. The purpose of this dual design is to provide the support needed to advance any transseptal sheath into the left atrium while reducing the risk of inadvertent perforation.

 About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, Boston (USA) and, London (U.K.). For more information, visit www.baylismedical.com.  

 Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

 

©-Copyright Baylis Medical Company Inc., 2014 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. ProTrack™ is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use.

CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Randomized Controlled Trial Demonstrates Radiofrequency Transseptal Needle Provides Added Benefits over Conventional Needle

Randomized Controlled Trial Demonstrates Radiofrequency Transseptal Needle Provides Added Benefits over Conventional Needle

Date:

FOR IMMEDIATE RELEASE

Randomized Controlled Trial Demonstrates Radiofrequency Transseptal Needle Provides Added Benefits over Conventional Needle

Montreal, Canada (September 27, 2013) – The results of a randomized controlled trial comparing the safety and effectiveness of the radiofrequency  NRG® Transseptal Needle to a conventional mechanical needle were published this month in The Journal of the American Heart Association. Conducted by electrophysiologists at the University of California, San Francisco, the study shows that the radiofrequency  NRG® needle was successful in completing the transseptal puncture in a number of procedures where the conventional needle failed to do so. There was no difference observed in the rate of adverse events. The radiofrequency NRG® needle also significantly reduced median transseptal procedure time. A further benefit was seen in that the radio frequency NRG® needle produced less grossly visible plastic shavings (0%) compared to the mechanical needle (33.3%).

The transseptal procedure is commonly part of atrial fibrillation ablation cases. It is a challenging and specialized procedure used to gain access to the left atrium of the heart.

Dr. Gregory Marcus, Director of Clinical Research for the UCSF Division of Cardiology, and senior author of the study, believes the NRG® needle improves transseptal procedure efficacy and efficiency: “Previous observational studies have suggested that radiofrequency assisted transseptal puncture may provide superior benefits over a regular mechanical needle. Our study provides the first randomized clinical evidence to suggest increased effectiveness and efficiency of the RF needle.”

This randomized, controlled trial included 72 patients undergoing cardiac catheter ablation procedures with a planned transseptal puncture. Subjects were randomized on a 1:1 basis to receive transseptal puncture with either a radiofrequency needle or a conventional needle. The median time to achieve transseptal left atrial access was 68% shorter using the NRG® needle as compared to the conventional needle (2.3 minutes versus 7.3 minutes, on an intention-to-treat basis). Failure to achieve transseptal access with the assigned needle did not occur with the NRG® needle, whereas the conventional needle failed on ten occasions (27.8%). In these 10 failed instances, subsequent crossover to the NRG® needle enabled a successful transseptal procedure. Ex vivo preprocedural testing found that the conventional needle produced visible plastic shavings in one-third of the cases whereas the NRG® needle did not produce any such plastic shavings.

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, Boston (USA), London (U.K.). For more information, visit www.baylismedical.com.

Contact

Luc Desaulniers
Communications  Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

©-Copyright Baylis Medical Company Inc., 2013 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. NRG® is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Baylis Medical strengthens U.S. presence with new office in Greater Boston

Baylis Medical strengthens U.S. presence with new office in Greater Boston

Date:

FOR IMMEDIATE RELEASE

Baylis Medical strengthens U.S. presence with new office in Greater Boston

Burlington, Mass. – (May 21, 2013) – Baylis Medical, a leading supplier of high-technology interventional cardiology and radiology products, is pleased to announce the official opening of its new offices in Burlington, Mass. The opening of the Boston-area office is a part of Baylis Medical’s ongoing global expansion project. Baylis Medical currently employs 200 employees globally and plans to hire additional employees this year.

Baylis Medical’s business has grown substantially over the past 24 months with an expanding sales force and the successful launch of several new products. The Boston office expansion was warranted by this growth. “The new office represents our commitment towards our continued growth in the U.S. market through direct sales, strengthened operational capabilities and enhanced technical support,” said Frank Baylis, President.

The new office will also bring in new opportunities for Baylis Medical. “Boston is a hub of medical device activities, and we are looking forward to tapping into the local expertise as we continue to expand our presence,” noted Baylis. “We will be looking to recruit more members to our team in the near future.”

“I welcome Baylis Medical to Massachusetts and look forward to them strengthening our innovation economy by creating jobs and economic development,” said Governor Deval Patrick.

Through the Massachusetts Life Sciences Center, Massachusetts is investing $1 billion over 10 years in the growth of the state’s life sciences supercluster. These investments are being made under the Massachusetts Life Sciences Initiative, proposed by Governor Patrick in 2007, and passed by the State Legislature and signed into law by Governor Patrick in 2008.

Massachusetts officials first met with Baylis Medical at the AdvaMed 2012 conference in Boston last October. “Congratulations to Baylis Medical on the opening of its first U.S. office,” said Susan Windham-Bannister, Ph.D., President & CEO of the Massachusetts Life Sciences Center (MLSC). “We are pleased that the company has chosen Massachusetts as the home for its U.S. operations. The company\'s portfolio of products, ranging from chronic pain management to radiology, are a great addition to our life sciences community, and we are confident that Massachusetts is the best place for Baylis Medical to continue to grow its business.”

“Burlington is pleased to welcome Baylis and its employees to town, and we hope they fully immerse themselves in all that Burlington has to offer,” said Massachusetts State Representative Kenneth I. Gordon. “The opening of Baylis Medical’s location demonstrates the recognition of Burlington as an important high tech center.”

“Baylis Medical has discovered what scores of other medtech companies now know – Massachusetts is a great place to establish a foothold in the American medical market,” said Tom Sommer, President of the Massachusetts Medical Device Industry Council (MassMEDIC). “We welcome the expansion of yet another Canadian medical device company in Massachusetts.”

“I join the Governor in welcoming Baylis Medical to Massachusetts,” said Tom Gradel, Acting Director of the Massachusetts Office of International Trade & Investment. “Baylis Medical will join a broad and deep ecosystem in the global hub of life sciences.”

Baylis Medical’s new office is located at the following address:
 
50 Mall Road
Suite G18
Burlington, MA 01803
 
About Baylis Medical
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, London, U.K. and Boston, Mass. For more information, visit www.baylismedical.com.  
 
About the Massachusetts Life Sciences Center
The Massachusetts Life Sciences Center (MLSC) is a quasi-public agency of the Commonwealth of Massachusetts tasked with implementing the Massachusetts Life Sciences Act, a 10-year, $1-billion initiative that was signed into law in June of 2008. The MLSC’s mission is to create jobs in the life sciences and support vital scientific research that will improve the human condition. This work includes making financial investments in public and private institutions that are advancing life sciences research, development and commercialization as well as building ties among sectors of the Massachusetts life sciences community. For more information, visit www.masslifesciences.com.
 

Luc Desaulniers             
Communications Associate       
Baylis Medical Company       
Tel : 514-488-9801        
ldesaulniers@baylismedical.com   

Angus McQuilken
Vice President for Communications and Marketing
Massachusetts Life Sciences Center
Tel : 617-921-7749
amcquilken@masslifesciences.com

This announcement is not intended to be a commercial endorsement by the MLSC of any products or services provided or developed by the entities referenced in this release.

###
 

Largest Case Series of New Radiofrequency Guidewire Shows Positive Results

Largest Case Series of New Radiofrequency Guidewire Shows Positive Results

Date:

FOR IMMEDIATE RELEASE

Largest Case Series of New Radiofrequency Guidewire Shows Positive Results

Montreal, Canada – (August 25, 2012) – Published in this month’s issue of the Journal of Vascular and Interventional Radiology is the largest case series to date using the PowerWireTM RF Guidewire. The retrospective study, published by Dr. Marcelo Guimaraes and colleagues at the Medical University of South Carolina (MUSC), describes the experience and outcomes of using the PowerWire™ RF Guidewire to cross chronic, symptomatic central venous occlusions (CVOs) that are resistant to standard techniques. The PowerWire™ RF Guidewire was successful at crossing 100% of the occlusions in 42 patients.

Successful crossing of lesions using the PowerWireTM RF Guidewire was achieved in 100% of cases with a global (major) complication rate of 2.3%. Forty of 42 patients were symptom-free and were able to continue dialysis at 6 and 9 months follow up. On the PowerWire™ RF Guidewire’s performance, Dr. Guimaraes comments: “The results of this technique are impressive. Because we use radiofrequency wire recanalization only after failure of conventional endovascular techniques, the patients would have either been left untreated or the alternative would be an open chest vascular by-pass surgery.”

A total of 43 recanalizations were performed in 42 patients using the PowerWireTM RF Guidewire between January 2008 and December 2011. In all patients, previous attempts at recanalization with conventional techniques and devices had failed. The authors conclude by advocating the use of the PowerWireTM RF Guidewire in select cases of chronic, symptomatic CVOs that are resistant to crossing with standard endovascular techniques. Central venous occlusions may be present in up to 38% of patients with a centrally placed dialysis catheter, and up to 24% of these occlusions cannot be crossed using conventional techniques. These patients have few treatment options and are often living with painful symptoms including swelling of the face, neck, and arms.

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, London (U.K.). For more information, visit www.baylismedical.com.

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

 

 

©-Copyright Baylis Medical Company Inc., 2013 Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. PowerWire™ is a trademark or registered trademark of Baylis Medical Company Inc. in the United States of America and/or other countries.


Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Baylis Medical Launches NRG® Transseptal Needle with Radiopaque Marker

Baylis Medical Launches NRG® Transseptal Needle with Radiopaque Marker

Date:

FOR IMMEDIATE RELEASE

Baylis Medical Launches NRG® Transseptal Needle with Radiopaque Marker

Stanford- California (June 12, 2012) – Baylis Medical is pleased to announce the release of its new radiofrequency NRG® Transseptal Needle with radiopaque marker. The radiopaque marker allows physicians to precisely visualize the tip of the needle prior to puncturing the septum of the heart during the transseptal puncture procedure.

The transseptal puncture procedure is used to gain access to the left side of the heart in order to perform various treatments. The past few years have seen a tremendous growth in the number of transseptal procedures performed as more cardiac treatments require this minimally invasive technique. These cardiac treatments include: atrial fibrillation ablation, mitral valve repair and left atrial appendage occlusion.

The transseptal puncture is a challenging procedure with the potential for serious adverse events if the puncture is unintentionally made in the incorrect location. Now, by using the radiofrequency NRG® Transseptal Needle with radiopaque marker, physicians can more readily locate the tip of the needle. This allows them to confidently guide the needle throughout the transseptal procedure. 

Dr. Al-Ahmad of Stanford Hospital and Clinics sees important value in this new feature: “In performing the transseptal procedure, there is potential of inadvertently puncturing in the wrong location. The radiopaque tipped needle can help doctors in doing in the procedure by allowing them to visualize the very tip of the needle. Very simply, I like to see where I am.”  

About Baylis Medical
Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, London, U.K. and Boston, Mass. For more information, visit www.baylismedical.com.  

Contact
Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

 

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Baylis Medical Executives Win Entrepreneur Of The Year Award

Baylis Medical Executives Win Entrepreneur Of The Year Award

Date:

FOR IMMEDIATE RELEASE

Baylis Medical Executives Win Entrepreneur Of The Year Award

Montreal - Canada (October 10, 2011) – During a ceremony held last Friday, Frank Baylis, President of Baylis Medical Inc. and Kris Shah, Executive Vice President & Chief Technology Officer, were named Ernst & Young’s 2011 Quebec Health Sciences Entrepreneurs Of The Year.

The Entrepreneur Of The Year Award recognizes Frank Baylis and Kris Shah for their longstanding success in the Canadian medical device industry. In Baylis Medical’s formative years, the company’s main operations consisted of the importation and distribution of medical devices into the Canadian market. From this beginning, the company has transformed itself into a developer and manufacturer of innovative, high-technology medical devices that are sold around the world. “Though the award was in our personal names, the reality is that any such victory is really the result of a great team effort. Kris and I are lucky and honoured to be surrounded by an outstanding team of engineers, technical staff, sales people, production staff, and more, who all contribute to the success of the company” said Frank Baylis.

A strong commitment to delivering innovative products has earned the company not only commercial success, but the interest from large medical device conglomerates. Baylis Medical presently has development partnerships with various major medical device companies.

This prestigious award falls concurrently on Baylis Medical’s 25th anniversary.

The Entrepreneur Of The Year awards honor the spirit and contribution of entrepreneurs here and around the world. Nominees are reviewed by an independent judging panel, which is composed of several distinguished business leaders and previous award recipients. The 2011 Quebec region judging panel consisted of Jean Cloutier, Vice President, Operations and Finance, Outdoor Gear Canada (OGC); Jean Gattuso, President and Chief Executive Officer, A. Lassonde Inc.; Nina Gupta, President, Greenlite Lighting Corporation; Andrée-Lise Méthot, Founder and Senior Partner, Cycle Capital Management; Pascal Pilon, President and CEO, Averna; Alexandre Taillefer, Partner, XPND Capital; Étienne Veilleux, President and CEO, Distech Controls Inc.

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of Interventional Cardiology and Interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, and London, U.K. For more information, please visit www.baylismedical.com.  

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

Baylis Medical continues its growth in interventional cardiology

Baylis Medical continues its growth in interventional cardiology

Date:

FOR IMMEDIATE RELEASE

Baylis Medical continues its growth in interventional cardiology, interventional radiology and in the Canadian distribution business

(Montreal, 13 October 2009) Last week we announced the news that Kimberly Clark had purchased the pain management business of Baylis Medical. While the pain management business was certainly a big part of our company, it is important to note that Kimberly Clark did not purchase our three other businesses.

These other businesses consist of interventional cardiology, interventional radiology, and Canadian distribution. Baylis Medical will continue run and grow these businesses, each of which have excellent growth opportunities in front of them. Specifically in our interventional radiology business, we anticipate launching within the next 6 months a full suite of interventional radiology products geared at treating chronic total occlusions. In our cardiology business, we plan on releasing a series of transseptal catheters to complement our ground breaking NRG™ RF Transseptal Needle. Finally, in our Canadian distribution business, we have a recently signed on to represent Cyberonics implantable epilepsy stimulator in Canada that will have an immediate positive impact on our sales.

At Baylis Medical we are very proud of our long standing association with Kimberly Clark. During the next 12 to 18 months we will be working very closely with Kimberly Clark to transition the pain management business over to them. However as you can see, we will also be very busy with the new, excellent opportunities we have coming in our three other businesses.

 

For more information:

Luc Desaulniers, Marketing & Communications
(514) 488-9801
ldesaulniers@baylismedical.com

 

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use. CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

New Technique Uses Radiofrequency for Transseptal Puncture

New Technique Uses Radiofrequency for Transseptal Puncture

Date:

FOR IMMEDIATE RELEASE

New Technique Uses Radiofrequency for Transseptal Puncture

Chicago - Illinois (August 15, 2008) – Baylis Medical announced today the successful, first-in-human, use of a novel medical device that utilizes radiofrequency energy to perform the transseptal puncture. This first-in-human use of the radiofrequency NRG™ Transseptal Needle was performed as an adjunct to an atrial fibrillation ablation at the University of Chicago by Dr. Bradley Knight. The patient had been referred to Dr. Knight after failure to complete the transseptal puncture at another hospital using a standard transseptal needle.

The previous procedure had failed due to scar formation on the atrial septum of the heart, which led to the inability to complete the transseptal puncture. The radiofrequency NRG™ Transseptal Needle utilizes a novel radiofrequency energy technology which is especially useful in patients that have scar formation on their septum. Using this device, Dr. Knight was able to pass the needle smoothly into the left atrium and complete the entire ablation procedure. Dr. Knight believes that it could be the new standard of care, as he stated to the University of Chicago Chronicle: “In a few years, hopefully we’ll look back and think how silly it was the way we were poking needles through like that.”   

 
The transseptal puncture, which is a requirement for atrial fibrillation ablation, is a challenging and specialized procedure used to gain access to the left atrium of the heart. If the puncture is unintentionally made in the incorrect location, it may lead to serious adverse events. The standard transseptal needle utilizes a basic design and can require uncontrolled mechanical force to be used. However, with the new NRG™ Transseptal Needle, the transseptal puncture can be accomplished in a controlled manner with increased safety.  

About Baylis Medical

Baylis Medical develops and markets high-technology medical devices used in the fields of interventional cardiology and interventional radiology. The company’s core expertise lies in electrosurgical systems that are used to deliver various therapeutic treatments. The company has offices in Montreal, Toronto, Vancouver, and London, U.K. For more information, please visit www.baylismedical.com.  

Contact

Luc Desaulniers
Communications Associate
Baylis Medical Company
Tel: 514-488-9801
ldesaulniers@baylismedical.com
http://www.baylismedical.com

###

© Copyright Baylis Medical Company Inc., 2008. Baylis Medical Company Inc. reserves the right to change specifications or to incorporate design changes without notice and without incurring any obligation relating to equipment previously manufactured or delivered. NRG™ and the Baylis Medical logo are trademarks or registered trademarks of Baylis Medical Company Inc. in the United States of America and/or other countries.

Before use, consult product labels and inserts for any indications, contraindications, hazards, warnings, cautions and instructions for use.
CAUTION: Federal Law (USA) restricts the use of this device to or by the order of a physician.

Patents Pending and/or issued